在怀孕前3个月内与新生儿结果相关的母体非活化COVID-19疫苗接种
Zhihui Chen1,2,3, Xingbo Mu1,2,3, Xinyan Wang2,4
1Department of Neonatology, Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin 300100, China.
Vaccines
|November 25, 2023
概括
怀孕前不活化COVID-19疫苗接种对新生儿结局没有不良影响. 这项研究没有发现过早分娩的显著差异,对于妊娠年龄来说很小,或接种疫苗的母亲的NICU入院.
科学领域:
- 产科和妇科 产科和妇科
- 新生儿健康 新生儿健康
- 免疫学 免疫学 免疫学
背景情况:
- 关于非活化COVID-19疫苗接种对新生儿结果的影响的数据有限.
- 在怀孕之前评估母亲的疫苗接种情况对于围产期健康至关重要.
研究的目的:
- 调查在怀孕前3个月内给予的非活化COVID-19疫苗接种与新生儿不良结果之间的关联.
- 为了比较接种疫苗和未接种疫苗的母亲产生的婴儿之间的新生儿结局.
主要方法:
- 在2022年3月1日至6月30日期间对单子活产的队列研究.
- 新生儿分为接种疫苗 (孕妇在怀孕前3个月内接种疫苗) 和未接种疫苗的组.
- 对新生儿结局的分析,包括早产,对于妊娠年龄来说小,以及NICU入院,调整混因子.
主要成果:
- 接种疫苗 (n=369) 和未接种疫苗 (n=487) 组之间的早产率没有统计学上显著的差异.
- 对于妊娠年龄或新生儿重症监护室入院的新生儿小的比例没有显著差异.
- 对社会经济地位和母亲特征进行控制的调整分析证实,新生儿结局没有显著差异.
结论:
- 怀孕前不活化的COVID-19疫苗接种与新生儿不良结果无关.
- 在怀孕之前对母亲进行疫苗接种似乎是安全的,这与新生儿的健康指标有关.
- 强调考虑COVID-19疫苗接种预设的重要性.
更多相关视频
09:09Generating a Reproducible Model of Mid-Gestational Maternal Immune Activation using PolyI:C to Study Susceptibility and Resilience in Offspring
Published on: August 17, 2022
1.7K
08:50A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development
Published on: June 24, 2020
3.8K
相关概念视频
01:22Development of Immunocompetence
315
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
315
01:07Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K